PL2885641T3 - Metody przewidywania ryzyka rozwoju nadciśnienia tętniczego krwi - Google Patents

Metody przewidywania ryzyka rozwoju nadciśnienia tętniczego krwi

Info

Publication number
PL2885641T3
PL2885641T3 PL13830006T PL13830006T PL2885641T3 PL 2885641 T3 PL2885641 T3 PL 2885641T3 PL 13830006 T PL13830006 T PL 13830006T PL 13830006 T PL13830006 T PL 13830006T PL 2885641 T3 PL2885641 T3 PL 2885641T3
Authority
PL
Poland
Prior art keywords
methods
predicting risk
developing hypertension
hypertension
developing
Prior art date
Application number
PL13830006T
Other languages
English (en)
Inventor
James V. Snider
Original Assignee
Critical Care Diagnostics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Care Diagnostics, Inc. filed Critical Critical Care Diagnostics, Inc.
Publication of PL2885641T3 publication Critical patent/PL2885641T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
PL13830006T 2012-08-16 2013-08-16 Metody przewidywania ryzyka rozwoju nadciśnienia tętniczego krwi PL2885641T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261683956P 2012-08-16 2012-08-16
PCT/US2013/055417 WO2014028875A1 (en) 2012-08-16 2013-08-16 Methods for predicting risk of developing hypertension
EP13830006.6A EP2885641B1 (en) 2012-08-16 2013-08-16 Methods for predicting risk of developing hypertension

Publications (1)

Publication Number Publication Date
PL2885641T3 true PL2885641T3 (pl) 2018-04-30

Family

ID=50100476

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13830006T PL2885641T3 (pl) 2012-08-16 2013-08-16 Metody przewidywania ryzyka rozwoju nadciśnienia tętniczego krwi

Country Status (16)

Country Link
US (3) US9523696B2 (pl)
EP (2) EP3282258A1 (pl)
JP (3) JP6298466B2 (pl)
CN (2) CN107478841A (pl)
AU (2) AU2013302451B2 (pl)
CA (1) CA2882133A1 (pl)
DK (1) DK2885641T3 (pl)
ES (1) ES2656897T3 (pl)
HK (1) HK1250782A1 (pl)
IN (1) IN2015DN01259A (pl)
MX (2) MX358541B (pl)
NO (1) NO2983845T3 (pl)
PL (1) PL2885641T3 (pl)
RU (2) RU2683026C2 (pl)
SG (2) SG10201704311VA (pl)
WO (1) WO2014028875A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002218026A1 (en) 2000-11-09 2002-05-21 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
DK1532269T3 (da) 2002-05-09 2012-03-12 Brigham & Womens Hospital 1L1RL-1 som markør for kardiovaskulær sygdom
EP3255432B1 (en) 2006-04-24 2019-01-23 Critical Care Diagnostics, Inc. Predicting mortality and detecting severe disease
ATE545032T1 (de) 2006-05-01 2012-02-15 Critical Care Diagnostics Inc Diagnose von herz-kreislauf-erkrankung
EP3378955A1 (en) 2008-04-18 2018-09-26 Critical Care Diagnostics, Inc. Predicting risk of major adverse cardiac events
US8420785B2 (en) 2010-04-09 2013-04-16 Critical Care Diagnostics, Inc. Soluble human ST-2 antibodies and assays
WO2012141844A2 (en) 2011-03-17 2012-10-18 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
MX351428B (es) 2011-07-18 2017-10-13 Critical Care Diagnostics Inc Métodos in vitro para correlacionar el nivel de sr2 solubre y la eficiencia de terapia de ejercicio en un sujeto que tiene una enfermedad cardiovascular.
CA2873896A1 (en) 2012-05-18 2013-11-21 Critical Care Diagnostics, Inc. Methods for treating or predicting risk of a ventricular tachyarrhythmia event
EP2884908B1 (en) * 2012-08-09 2021-11-24 Smith & Nephew, Inc. Intra-operatively adjustable cutting guide
PL2885641T3 (pl) 2012-08-16 2018-04-30 Critical Care Diagnostics, Inc. Metody przewidywania ryzyka rozwoju nadciśnienia tętniczego krwi
CA2882303A1 (en) 2012-08-21 2014-02-27 Critical Care Diagnostics, Inc. Multimarker risk stratification
KR102328327B1 (ko) 2014-09-26 2021-11-22 소마로직, 인크. 심혈관 위험 사건 예측 및 이의 용도
US11708608B2 (en) 2014-11-10 2023-07-25 Genentech, Inc. Therapeutic and diagnostic methods for IL-33-mediated disorders
TWI705976B (zh) 2014-11-10 2020-10-01 美商建南德克公司 抗介白素-33抗體及其用途
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
RU2677611C1 (ru) * 2018-04-16 2019-01-17 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Способ прогнозирования неблагоприятных сердечно-сосудистых событий в течение 12 месяцев у больных хронической сердечной недостаточностью с рецидивом стенокардии после реваскуляризации миокарда
US11551817B2 (en) 2020-01-14 2023-01-10 International Business Machines Corporation Assessing unreliability of clinical risk prediction
AU2021236306A1 (en) 2020-03-13 2022-09-15 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
US20220218292A1 (en) * 2021-01-14 2022-07-14 Apple Inc. User interfaces for monitoring health
RU2767266C1 (ru) * 2021-05-27 2022-03-17 Федеральное государственное бюджетное научное учреждение «Томский национальный исследовательский медицинский центр Российской академии наук» (Томский НИМЦ) Способ прогнозирования однолетнего риска неблагоприятных сердечно-сосудистых событий у мужчин после декомпенсации хронической сердечной недостаточности с сохранной фракцией выброса левого желудочка сердца и синдромом обструктивного апноэ во сне
CN114350670B (zh) * 2022-03-18 2022-06-14 北京市心肺血管疾病研究所 特异性识别可溶性st2蛋白的核酸适配体及其应用
CN115188465B (zh) * 2022-06-27 2025-09-26 深圳技术大学 急性加重的预测方法及装置、电子设备和存储介质

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001218871A1 (en) * 2000-03-21 2001-10-03 Takao Arai Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
AU2002218026A1 (en) 2000-11-09 2002-05-21 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
WO2003040691A2 (en) * 2001-11-05 2003-05-15 The Brigham And Women's Hospital, Inc. Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases
DK1532269T3 (da) 2002-05-09 2012-03-12 Brigham & Womens Hospital 1L1RL-1 som markør for kardiovaskulær sygdom
WO2005041893A2 (en) 2003-10-31 2005-05-12 Queststar Medical, Inc. Detection of acute myocardial infarction biomarkers
CA2587601C (en) * 2004-12-03 2017-11-07 Rhode Island Hospital Diagnosis and treatment of alzheimer's disease
EP3255432B1 (en) * 2006-04-24 2019-01-23 Critical Care Diagnostics, Inc. Predicting mortality and detecting severe disease
US20090305265A1 (en) 2006-04-27 2009-12-10 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
ATE545032T1 (de) 2006-05-01 2012-02-15 Critical Care Diagnostics Inc Diagnose von herz-kreislauf-erkrankung
HUE025058T2 (en) 2006-05-02 2016-01-28 Critical Care Diagnostics Inc Differential diagnosis of pulmonary and cardiovascular disease
WO2007130627A2 (en) * 2006-05-04 2007-11-15 The Brigham And Women's Hospital, Inc. Il-33 in the treatment and diagnosis of diseases and disorders
GB0703514D0 (en) * 2007-02-23 2007-04-04 Univ Ulster Use of riboflavin
CA2697357A1 (en) 2007-04-16 2008-10-30 John T. Mcdevitt Cardibioindex/cardibioscore and utility of salivary proteome in cardiovascular diagnostics
EP2301626B1 (en) * 2007-08-03 2013-01-16 B.R.A.H.M.S GmbH Antibiotic for use in local infection
EP3378955A1 (en) 2008-04-18 2018-09-26 Critical Care Diagnostics, Inc. Predicting risk of major adverse cardiac events
CN107085114B (zh) * 2008-10-07 2021-05-25 B.R.A.H.M.S有限公司 用于预测初次不利事件的生物标志物
CN102472752B (zh) * 2009-08-28 2015-08-19 B.R.A.H.M.S有限公司 用于不良事件的预后的降钙素原
US8420785B2 (en) * 2010-04-09 2013-04-16 Critical Care Diagnostics, Inc. Soluble human ST-2 antibodies and assays
GB201013151D0 (en) * 2010-08-04 2010-09-22 Isis Innovation Diagnostic method
WO2012141844A2 (en) 2011-03-17 2012-10-18 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
MX351428B (es) * 2011-07-18 2017-10-13 Critical Care Diagnostics Inc Métodos in vitro para correlacionar el nivel de sr2 solubre y la eficiencia de terapia de ejercicio en un sujeto que tiene una enfermedad cardiovascular.
US20130157290A1 (en) * 2011-12-16 2013-06-20 Yves Levy Soluble st2 as a marker for disease
CA2873896A1 (en) * 2012-05-18 2013-11-21 Critical Care Diagnostics, Inc. Methods for treating or predicting risk of a ventricular tachyarrhythmia event
PL2885641T3 (pl) 2012-08-16 2018-04-30 Critical Care Diagnostics, Inc. Metody przewidywania ryzyka rozwoju nadciśnienia tętniczego krwi
CA2882303A1 (en) 2012-08-21 2014-02-27 Critical Care Diagnostics, Inc. Multimarker risk stratification
EP3092488A4 (en) 2014-01-10 2017-07-12 Critical Care Diagnostics, Inc. Methods and systems for determining risk of heart failure
USD770057S1 (en) 2014-04-14 2016-10-25 Critical Care Diagnostics, Inc. Blood test kit
USD800332S1 (en) * 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
USD800333S1 (en) * 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker

Also Published As

Publication number Publication date
SG10201704311VA (en) 2017-07-28
US10041957B2 (en) 2018-08-07
RU2019107598A (ru) 2019-03-28
US9523696B2 (en) 2016-12-20
EP2885641A4 (en) 2016-03-23
SG11201501200XA (en) 2015-04-29
DK2885641T3 (da) 2018-01-29
NO2983845T3 (pl) 2017-12-16
AU2013302451A1 (en) 2015-03-05
RU2683026C2 (ru) 2019-03-26
US20140051773A1 (en) 2014-02-20
JP2015526727A (ja) 2015-09-10
MX382403B (es) 2025-03-13
EP2885641A1 (en) 2015-06-24
HK1250782A1 (en) 2019-01-11
JP6757757B2 (ja) 2020-09-23
AU2013302451B2 (en) 2019-01-17
CN107478841A (zh) 2017-12-15
JP2020196757A (ja) 2020-12-10
CN104737023B (zh) 2017-07-28
HK1208075A1 (en) 2016-02-19
JP6298466B2 (ja) 2018-03-20
HK1212022A1 (en) 2016-06-03
CN104737023A (zh) 2015-06-24
US20180335437A1 (en) 2018-11-22
EP2885641B1 (en) 2017-11-01
EP3282258A1 (en) 2018-02-14
MX358541B (es) 2018-08-24
US20170219610A1 (en) 2017-08-03
WO2014028875A1 (en) 2014-02-20
IN2015DN01259A (pl) 2015-07-03
JP2018135330A (ja) 2018-08-30
RU2015108959A (ru) 2016-10-10
CA2882133A1 (en) 2014-02-20
MX2015002061A (es) 2015-06-05
AU2019202597A1 (en) 2019-05-02
ES2656897T3 (es) 2018-02-28

Similar Documents

Publication Publication Date Title
SG11201501200XA (en) Methods for predicting risk of developing hypertension
IL276488A (en) Method of predicting breast cancer prognosis
GB201102014D0 (en) Method for predicting risk of developing cancer
EP2686689A4 (en) METHODS OF PREDICTING RISK OF UNDESIRABLE CLINICAL RESULT
EP2702513A4 (en) DETERMINATION OF RECOMMENDATION DATA
EP2717100A4 (en) TONER
EP2710430A4 (en) Toner
PL2825719T3 (pl) Sposób obsługi odwiertów
EP2717099A4 (en) TONER
EP2710432A4 (en) Toner
EP2691815A4 (en) TONER
EP2710431A4 (en) TONER
EP2794330A4 (en) METHOD AND MODULE FOR DETERMINING AT LEAST ONE REFERENCE VALUE
DK2879615T3 (da) Fremgangsmåde til at bestemme sandsynlighed for brunst
SMT202300060T1 (it) Metodo di valutazione del rischio di pml
EP2753982A4 (en) TONER
BR112015002542A2 (pt) método de caracterização de um objeto
GB201104556D0 (en) Biomarkers
GB2510539B (en) Biomarkers of cancer
AP2014007806A0 (en) Method for floating
GB201215942D0 (en) Method of treatent
SG11201502998UA (en) Methods and kits for increasing or predicting oil yield
ZA201503833B (en) Method of hemoglobin-f determination
EP2780766A4 (en) DEVICES FOR QUANTIFYING TEMPORARY TIME
ZA201400950B (en) Method for predicting risk of hypertension associated with anti-angiogenesis therapy